MSE
ESPR

MUFG Securities EMEA’s Esperion Therapeutics ESPR Stock Holding History

MUFG Securities EMEA’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-180,000
Closed -$13M – 615
2018
Q1 		$13M Hold
180,000
– – 0.28% 80
2017
Q4 		$11.9M Hold
180,000
– – 0.28% 68
2017
Q3 		$9.02M Buy
+180,000
New +$8.68M 0.32% 39

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MUFG Securities EMEA's ESPR Position: Q2 2018 in Review

MUFG Securities EMEA sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 180,000 shares — an estimated $13M sold.

MUFG Securities EMEA first reported a position in ESPR in Q3 2017 and held it in 3 quarters. The position peaked at $13M in Q1 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • MUFG Securities EMEA reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • MUFG Securities EMEA sold 180,000 Esperion Therapeutics shares in Q2 2018, an estimated $13M.
  • MUFG Securities EMEA first reported a position in Esperion Therapeutics in Q3 2017 and held it in 3 quarters.
  • MUFG Securities EMEA's Esperion Therapeutics position peaked at $13M in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on MUFG Securities EMEA's 13F filing for Q2 2018, filed 1 Aug 2018.